高级别浆液性卵巢癌的影像基因组学:癌症基因组图谱卵巢癌影像研究组的多阅片者多机构研究
本研究为多阅片者、多机构回顾性分析,纳入92例高级别浆液性卵巢癌患者的术前腹盆CT,评估8名放射科医生对CT特征的观察者间一致性及其与疾病进展时间和转录组分型的关联,并构建影像风险评分。部分特征一致性强度高(如胸水及腹水α=0.78),部分较低(如脾实质转移α=0.08);腹膜病变部位、膈上淋巴结肿大等与较短进展时间相关。
要点
- 胸水及腹水等部分CT特征观察者间一致性强度高(α=0.78),脾实质转移一致性低(α=0.08)
- 右 upper quadrant 腹膜病变、膈上淋巴结肿大、更多腹膜病变部位及卵巢肿块不可辨与较短进展时间相关
- 更多腹膜病变部位及直肠子宫陷凹植入与间充质型CLOVAR分型相关
核心结论
- 这些结果提供了一些证据表明这些影像特征具有临床和生物学有效性;部分特征观察者间一致性强度高,但其他特征的一致性有待提高。
研究设计与样本
- 多阅片者、多机构、经机构审查委员会批准、符合HIPAA的回顾性分析,纳入92例高级别浆液性卵巢癌患者(中位年龄61岁),分析初次肿瘤细胞减灭术前的腹盆CT,影像来自癌症影像档案;由癌症基因组图谱卵巢癌影像研究组的8名放射科医生独立记录CT特征。
关键影像表现/征象
- 原发卵巢肿块特征、可定义的肠系膜植入及浸润、其他植入、腹膜播散的存在与分布、胸水及腹水的大小与存在、淋巴结肿大及远处转移。
- 部分特征观察者间一致性强度高,例如胸水及腹水α=0.78;其他特征一致性较低,例如脾实质转移α=0.08。
- 右 upper quadrant 腹膜病变(P=0.0003)、膈上淋巴结肿大(P=0.0004)、更多腹膜病变部位(P=0.0006)及卵巢肿块不可辨(P=0.0037)与较短疾病进展时间相关。
- 更多腹膜病变部位(P=0.0025)及直肠子宫陷凹植入(P=0.0045)与CLOVAR间充质型相关。
- 影像特征组合对疾病进展时间具有预测信号(一致性指数=0.658;P=0.0006),对CLOVAR分型亦具有预测信号(均方偏差=1.776;P=0.0043)。
诊断标准与关键数值
- 观察者间一致性以α值评估:胸水及腹水α=0.78,脾实质转移α=0.08。
- 与较短疾病进展时间相关的特征:右 upper quadrant 腹膜病变P=0.0003、膈上淋巴结肿大P=0.0004、更多腹膜病变部位P=0.0006、卵巢肿块不可辨P=0.0037。
- 与CLOVAR间充质型相关的特征:更多腹膜病变部位P=0.0025、直肠子宫陷凹植入P=0.0045。
- 影像特征组合预测疾病进展时间的一致性指数=0.658(P=0.0006),预测CLOVAR分型的均方偏差=1.776(P=0.0043)。
临床应用与阅片要点
- 阅片时可关注右 upper quadrant 腹膜病变、膈上淋巴结肿大、腹膜病变部位数目及卵巢肿块是否可辨,这些特征与疾病进展时间相关。
- 评估腹膜病变部位数目及直肠子宫陷凹植入可能有助于提示CLOVAR间充质型。
- 部分CT特征观察者间一致性较低(如脾实质转移α=0.08),报告时需注意一致性差异。
局限性
- 部分特征观察者间一致性较低,例如脾实质转移α=0.08,原文指出这些特征的一致性有待提高。
- 原文结论称这些结果提供了一些证据表明影像特征具有临床和生物学有效性,语气为「some evidence」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate interradiologist agreement on assessments of computed tomography (CT) imaging features of high-grade serous ovarian cancer (HGSOC), to assess their associations with time-to-disease progression (TTP) and HGSOC transcriptomic profiles (Classification of Ovarian Cancer [CLOVAR]), and to develop an imaging-based risk score system to predict TTP and CLOVAR profiles. Materials and Methods This study was a multireader, multi-institutional, institutional review board-approved, HIPAA-compliant retrospective analysis of 92 patients with HGSOC (median age, 61 years) with abdominopelvic CT before primary cytoreductive surgery available through the Cancer Imaging Archive. Eight radiologists from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group developed and independently recorded the following CT features: characteristics of primary ovarian mass(es), presence of definable mesenteric implants and infiltration, presence of other implants, presence and distribution of peritoneal spread, presence and size of pleural effusions and ascites, lymphadenopathy, and distant metastases. Interobserver agreement for CT features was assessed, as were univariate and multivariate associations with TTP and CLOVAR mesenchymal profile (worst prognosis). Results Interobserver agreement for some features was strong (eg, α = .78 for pleural effusion and ascites) but was lower for others (eg, α = .08 for intraparenchymal splenic metastases). Presence of peritoneal disease in the right upper quadrant (P = .0003), supradiaphragmatic lymphadenopathy (P = .0004), more peritoneal disease sites (P = .0006), and nonvisualization of a discrete ovarian mass (P = .0037) were associated with shorter TTP. More peritoneal disease sites (P = .0025) and presence of pouch of Douglas implants (P = .0045) were associated with CLOVAR mesenchymal profile. Combinations of imaging features contained predictive signal for TTP (concordance index = 0.658; P = .0006) and CLOVAR profile (mean squared deviation = 1.776; P = .0043). Conclusion These results provide some evidence of the clinical and biologic validity of these image features. Interobserver agreement is strong for some features, but could be improved for others. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Vargas HA, Huang EP, Lakhman Y, et al. Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group. Radiology. 2017. PMID: 28641043. doi:10.1148/radiol.2017161870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。